The effect of morphine on glial cells as a potential therapeutic target for pharmacological development of analgesic drugs

Current Pain and Headache Reports

Volumn 14, Issue 2, 2010, Pages 96-104

  Hameed, Haroon ^a   Hameed, Mariam ^a   Christo, Paul J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesia; Chronic pain; Dependence; Dizocilpine; Glial cell; Ibudilast; Minocycline; Morphine; NMDA; Opioid receptor; Pain relief; Pentoxifylline; Propentofylline; Reward; Tolerance; Toll like receptor

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ANALGESIC AGENT; AV 333; DIZOCILPINE; IBUDILAST; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; KAPPA OPIATE RECEPTOR; MINOCYCLINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE; PACLITAXEL; PROPENTOFYLLINE; SLC 022; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ASTHMA; BRAIN ISCHEMIA; CHRONIC PAIN; DEGENERATIVE DISEASE; DIZZINESS; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERANCE; GLIA CELL; HUMAN; NEUROPATHIC PAIN; NEUROPATHY; OPIATE ADDICTION; PAIN; REVIEW; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

ANALGESICS, OPIOID; ANIMALS; CHRONIC DISEASE; DRUG DESIGN; DRUG SYNERGISM; DRUG TOLERANCE; HUMANS; MORPHINE; NEUROGLIA; PAIN;

EID: 77953541735     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-010-0093-y     Document Type: Review

References (60)

1. Hutchinson MR, Bland ST, Johnson KW, et al.: Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007, 7:98-111. This article discusses TLRs and modifying agents and their relevance to the future of the management of pain. It also includes detailed information related to the research regarding naloxone in the management of opioid side effects.
2. Coyle DE: Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 1998, 23:75-83.
3. McMahon SB (2002) Neuropathic pain mechanisms. In: Giamberardino MA (ed) Pain 2002-an updated review. Seattle: IASP Press, 155-164.
4. Nakajima K, Kohsaka S: Functional roles of microglia in the brain. Neurosci Res 1993, 17:187-203.
5. Milligan ED, Watkins LR: Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36.
6. Halassa MM, Fellin T, Haydon PG: The tripartite synapse: Roles for gliotransmission in health and disease. Trends Mol Med 2007, 13:54-63.
7. Pocock JM, Kettenmann H: Neurotransmitter receptors on microglia. Trends Neurosci 2007, 30:527-535.
8. Cao H, Zhang YQ: Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev 2008, 32:972-983.
9. Ji RR, Gereau RW 4th, Malcangio M, Strichartz GR: MAP kinase and pain. Brain Res Rev 2009, 60:135-148.
10. Watkins LR, Maier SF: The pain of being sick: Implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000, 51:29-57.
11. Minghetti L, Levi G: Microglia as effector cells in brain damage and repair: Focus on prostanoids and nitric oxide. Prog Neurobiol 1998, 54:99-125.
12. Hutchinson MR, Coats BD, Lewis SS, et al.: Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008, 22:1178-1189.
13. Malcangio M, Bowery NG, Flower RJ, Perretti M: Effect of interleukin-1 on the release of substance P from rat isolated spinal cord. Eur J Pharmacol 1996, 299:113-118.
14. Mika J: Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 2008, 60:297-307. This review discusses the roles of various cytokine-related cascades in addition to other TLR-related mechanisms in the generation of nonopioid receptor-mediated opioid effects and the agents that may be employed to modify them.
15. Obreja O, Rathee PK, Lips KS, et al.: IL-1 potentiates heatactivated currents in rat sensory neurons: Involvement of IL-1RI, tyrosine kinase, and protein kinase C. FASEB J 2002, 16:1497- 1503.
16. Flatters SJ, Fox AJ, Dickenson AH: Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res 2003, 984:54-62.
17. Moore KW, ÓGarra A, de Waal Malefyt R, et al.: Interleukin-10. Annu Rev Immunol 1993, 11:165-190
18. Avigen, Inc.: Available at www.avigen.com. Accessed November 2009.
19. Sawada M, Suzumura A, Hosoya H, et al.: Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J Neurochem 1999, 72:1466-1471.
20. Huber TS, Gaines GC, Welborn MB 3rd, et al.: Anticytokine therapies for acute inflammation and the systemic inflammatory response syndrome: IL-10 and ischemia/reperfusion injury as a new paradigm. Shock 2000, 13:425-434.
21. Merrill JE, Benveniste EN: Cytokines in inflammatory brain lesions: Helpful and harmful. Trends Neurosci 1996, 19:331- 338.
22. Fontaine V, Mohand-Said S, Hanoteau N, et al.: Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002, 22:RC216.
23. Tanga FY, Nutile-McMenemy N, Deleo JA: The CNS role of Tolllike receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A 2005, 102: 5856-5861.
24. Kim D, Kim MA, Cho IH, et al.: A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem 2007, 282:14975-14983.
25. Muzio M, Mantovani A: Toll-like receptors (TLRs) signalling and expression pattern. J Endotoxin Res 2001, 7:297-300.
26. Guo LH, Schluesener HJ: The innate immunity of the central nervous system in chronic pain: The role of Toll-like receptors. Cell Mol Life Sci 2007, 64:1128-1136. This article offers a detailed discussion on TLRs and their role in the development of various types of pain.
27. Takeda K, Akira S: TLR signaling pathways. Semin Immunol 2004, 16:3-9.
28. Watkins LR, Hutchinson MR, Rice KC, Maier SF: The "toll" of opioid-induced glial activation: Improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009, 30:581- 591. This is a very recent review of TLR receptors and the current foci of interest in the management of dependence, reward, and other opioid-related side effects.
29. Kakimura J, Kitamura Y, Takata K, et al.: Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J 2002, 16:601-603.
30. Tsuda M, Shigemoto-Mogami Y, Koizumi S, et al.: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424:778-783.
31. Horvath RJ, DeLeo JA: Morphine enhances microglial migration through modulation of P2X4 receptor signaling. J Neurosci 2009, 29:998-1005.
32. McMahon SB, Cafferty WB, Marchand F: Immune and glial cell factors as pain mediators and modulators. Exp Neurol 2005, 192:444-462.
33. Hutchinson MR, Zhang Y, Shridhar M, et al.: Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010, 24:83-95. This paper summarizes recent information regarding the highly central role of TLR-4 receptors with implications to the current developments in the opioidrelated tolerance and dependence modifying agents.
34. Juni A, Klein G, Pintar JE, Kest B: Nociception increases during opioid infusion in opioid receptor triple knock-out mice. Neuroscience 2007, 147:439-444.
35. Shu H, Hayashida M, Huang W, et al.: The comparison of effects of processed Aconiti tuber, U50488H and MK-801 on the antinociceptive tolerance to morphine. J Ethnopharmacol 2008, 117:158-165.
36. Ueda H, Ueda M: Mechanisms underlying morphine analgesic tolerance and dependence. Front Biosci 2009, 14:5260-5272. This is a highly detailed review of the protein pathways responsible for the development of opioid tolerance and dependence. This review includes discussions on protein kinase receptor phosphorylations, NMDA receptors, neurotrophins, and various other neuropeptides.
37. Xu M, Bruchas MR, Ippolito DL, et al.: Sciatic nerve ligationinduced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase. J Neurosci 2007, 27:2570-2581.
38. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW: Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007, 16:935-950. This review details the effectiveness of ibudilast in the management of opioid tolerance and reward.
39. Kishi Y, Ohta S, Kasuya N, et al.: Ibudilast: A non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovasc Drug Rev 2001, 19:215-225.
40. Fujimoto T, Sakoda S, Fujimura H, Yanagihara T: Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999, 95:35-42.
41. Feng J, Misu T, Fujihara K, et al.: Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004, 10:494-498.
42. Harris GC, Aston-Jones G: Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 1994, 371:155-157. (Pubitemid 24284013)
43. Bland ST, Hutchinson MR, Maier SF, et al.: The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain Behav Immun 2009, 23:492-497. This review discusses the mechanism of action of AV411 and its relationship to TLRs.
44. Kest B, Mogil JS, Shamgar BE, et al.: The NMDA receptor antagonist MK-801 protects against the development of morphine tolerance after intrathecal administration. Proc West Pharmacol Soc 1993, 36:307-310.
45. Guo RX, Zhang M, Liu W, et al.: NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance. Neurosci Lett 2009, 467:95-99.
46. Morgan MM, Bobeck EN, Ingram SL: Glutamate modulation of antinociception, but not tolerance, produced by morphine microinjection into the periaqueductal gray of the rat. Brain Res 2009, 1295:59-66.
47. Schmidt AP, Tort AB, Silveira PP, et al.: The NMDA antagonist MK-801 induces hyperalgesia and increases CSF excitatory amino acids in rats: Reversal by guanosine. Pharmacol Biochem Behav 2009, 91:549-553.
48. Sweitzer SM, Pahl JL, DeLeo JA: Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci Lett 2006, 400:258-261.
49. Gwak YS, Crown ED, Unabia GC, Hulsebosch CE: Propentofylline attenuates allodynia, glial activation and modulates GABAergic tone after spinal cord injury in the rat. Pain 2008, 138:410-422.
50. Narita M, Miyatake M, Narita M, et al.: Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31:2476-2488.
51. Mika J, Wawrzczak-Bargiela A, Osikowicz M, et al.: Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain Behav Immun 2009, 23:75-84.
52. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res 2009, 196:168-179.
53. Li WW, Setzu A, Zhao C, Franklin RJ: Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. J Neuroimmunol 2005, 158:58-66.
54. Ledeboer A, Sloane EM,Milligan ED, et al.: Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005, 115:71-83.
55. Zanjani TM, Sabetkasaei M, Mosaffa N, et al.: Suppression of interleukin-6 by minocycline in a rat model of neuropathic pain. Eur J Pharmacol 2006, 538:66-72.
56. Piao ZG, Cho IH, Park CK, et al.: Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain 2006, 121:219-231.
57. Cui Y, Liao XX, Liu W, et al.: A novel role of minocycline: Attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun 2008, 22:114-123.
58. Wei T, Sabsovich I, Guo TZ, et al.: Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur J Pain 2009, 13:253-262.
59. Dorazil-Dudzik M, Mika J, Schafer MK, et al.: The effects of local pentoxifylline and propentofylline treatment on formalininduced pain and tumor necrosis factor-alpha messenger RNA levels in the inflamed tissue of the rat paw. Anesth Analg 2004, 98:1566-1573.
60. Liu J, Feng X, Yu M, et al.: Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett 2007, 412:268-272.